Physician profile
Christopher E Salem
NPI 1124273313
$4,265.72
in general payments reported to CMS, 2019-2025
39 companies · $934 in 2025
The $934 reported for 2025 was more than what 89% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $225 · 2021: $65.16 · 2022: $1,005 · 2023: $1,087 · 2024: $791 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Education: $61.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.71 |
| Education | $61.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $596.13 | 2022-2025 | Wegovy, Saxenda, Rybelsus |
| Amgen INC. | $509.00 | 2022-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $439.57 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $308.43 | 2020-2025 | Lokelma, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $216.05 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.51 | 2020-2024 | Lifevest |
| Pfizer INC. | $187.31 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.43 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.44 | 2025 | Caplyta |
| Impulse Dynamics (USA) INC. | $142.29 | 2022 | |
| Amarin Pharma, INC. | $123.42 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $110.15 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Inari Medical, INC. | $101.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $98.70 | 2022-2024 | Epclusa |
| Sunovion Pharmaceuticals INC. | $88.80 | 2019 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.